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The Interferon Inducible Gene: Viperin
Katherine A. Fitzgerald
The type I interferons (IFNs), IFN-a and -b, are key effector molecules of the immune response to viruses. The
anti-viral action of IFNs on virus-infected cells and surrounding tissues is mediated by expression of hundreds of
IFN-stimulated genes. Viperin (virus inhibitory protein, endoplasmic reticulum-associated, IFN-inducible) is an
Interferon stimulated gene (ISG), which is induced by type I, II, and III IFNs or after infection with a broad range
of DNA and RNA viruses. Recent evidence indicates that Viperin disrupts lipid rafts to block influenza virus
budding and release and interferes with replication of hepatitis C virus by binding to lipid droplets, small
organelles involved in lipid homeostasis that are essential for hepatitis C virus replication. Viperin is also
induced by nonviral microbial products such as lipopolysaccharide (LPS) and by a wide range of bacteria,
suggesting a broader role in innate antimicrobial defenses.
To survive infection the immune system deploys anarsenal of defensive measures to combat invading mi-
crobes (Biron 2001; Samuel 2001; Barnes and others 2002).
The type I interferons (IFNs) are among the earliest of these
defenses. The importance of type I IFNs is highlighted by the
enhanced susceptibility of IFN-a/bR-deficient mice to virus
infection (Kamijo and others 1994; Hwang and others 1995)
and the myriad of strategies employed by viruses to interfere
with their production and/or action and the antiviral activity
of the IFN-stimulated genes (ISGs) themselves [reviewed in
(Katze and others 2002)]. The workhorses of the type I IFN
system are these ISGs, several of which have been charac-
terized in detail. The mechanisms by which ISGs restrict viral
replication are ill-defined and are covered in this issue. Vi-
perin is one such example. The results of gene-profiling mi-
croarray studies showed that the Viperin gene is one of those
that is often most highly induced by a range of different
viruses (Boudinot and others 2000; Sun and Nie 2004; Helbig
and others 2005; Olofsson and others 2005; Severa and others
2006; Chan and others 2008), by the double-stranded RNA
analog poly(I-C) (Severa and others 2006), by the double-
stranded B-form DNA (poly-dAdT) (Kato and others 2006)
and by microbial products, such as lipopolysaccharide
(Olofsson and others 2005; Severa and others 2006), in vari-
ous cell types. While considerable progress has been made in
our understanding of how Viperin is turned on in cells, key
mechanistic insights into its mode of action are only begin-
ning to be elucidated.
Viperin (virus inhibitory protein, endoplasmic reticulum
[ER]-associated, IFN-inducible) was first identified in fish, as
virus induced gene (vig1), where it was shown to be induced
to high levels during infection of rainbow trout leukocytes
with viral hemorrhagic septicemia virus, a fish rhabdovi-
rus (Boudinot and others 2000). Its human homolog, cyto-
megalovirus-induced gene (cig5) [also known as radical
S-adenosyl methionine (SAM) domain-containing 2 in both
human and mouse], was similarly identified from primary
skin cultures incubated with inactivated human cytomega-
lovirus (HCMV). While examining the IFN-g response of
human macrophages, Chin and Cresswell (2001) identified a
unique IFN-g inducible gene, fragments of which were
identical to cig5, which they subsequently named Viperin.
The amino acid sequence of Viperin was then found to be
homologous to a rat gene, interferon-inducible gene ex-
pressed during bone formation (BEST5), expressed during
rat osteoblast differentiation. Viperin has since been found in
a wide range of organisms ranging from bony fish to
mammals (Fig. 1). Although IFN-g was capable of inducing
expression of Viperin, the type I IFNs were far more potent
activators. Additional studies revealed the ability of human
cytomegalovirus as well as the HCMV glycoprotein B (gB)
protein to potently upregulate Viperin gene expression
(Chin and Cresswell 2001).
The initial characterization of Viperin revealed its ability
to prevent the replication of HCMV. Over the last several
years, Viperin has been shown to have activity against a
range of additional viruses, including influenza virus, hep-
atitis C virus (HCV), dengue virus, alphaviruses, and retro-
viruses such as human immunodeficiency virus. The
mechanism by which Viperin restricts replication of all of
these viruses is not fully clear. In the case of HCMV, it was
shown that while ectopic expression of Viperin in fibroblasts
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had no effect on HCMV immediate early viral gene expres-
sion (IE1 and IE2), the synthesis of early late, (pp65), late
(gB), or true late (pp28) genes was significantly reduced in
cells expressing Viperin compared to control cells. Since ex-
pression of these proteins is indispensible for productive
HCMV infection, these studies indicated that Viperin likely
exerted its antiviral effects at a late stage in of the viral life
cycle (Chin and Cresswell 2001).
The human Viperin gene encodes a protein of 361 amino
acids with a predicted molecular mass of 42.2 kDa. Viperin
contains a 42-amino acid residue N-terminal amphipathic a-
helix that, in other proteins, is known to bind membranes and
induce membrane curvature (Drin and others 2007; Drin and
Antonny 2010). This is followed by a CX3CX2C motif, which is
found in the superfamily of SAM-dependent radical enzymes.
The radical SAM superfamily comprises more than 600 mem-
bers (Sofia and others 2001), and evidence suggests that the 3
conserved cysteine residues are part of an unusual iron-sulfur
cluster that uses SAM as a cofactor to form a radical that is
involved in catalysis. Thus, Viperin is also called radical SAM
domain-containing 2. Recent studies have provided clear proof
that Viperin is indeed a radical SAM enzyme (Duschene and
Broderick 2010; Shaveta and others 2010), although how this
relates to its antiviral activities is still unclear. A schematic
representation of the domain organization of Viperin is shown
in Fig. 2. The 42-amino acid N-terminal amphipathic a-helix is
critical for the antiviral action of Viperin. This region localizes
Viperin to the ER, where it has been shown to dimerize.
Expression of Viperin can interferewith the secretion of soluble
proteins from cells, although again, the relevance of these
findings to its anti-viral effects is not clear.
What has emerged is the ability of Viperin to inhibit in-
fluenza virus replication and insights into the mechanisms
underlying this effect have been uncovered (Wang and oth-
ers 2007). To infect cells, influenza binds the cell surface re-
ceptor, sialic acid, and is then internalized via endocytosis.
The low endosomal pH enables membrane fusion, thereby
releasing the viral genome into the cytosol and ultimately
into the nucleus, where viral mRNA synthesis and genome
replication occur. The viral mRNAs enter the cytosol and
initiate viral protein synthesis, whereas the transmembrane
glycoproteins, hemagglutinin and neuraminidase, traffic to
lipid rafts at the plasma membrane. Lipid rafts are essential
sites from where viral budding takes place (Zhang and
others 2000; Takeda and others 2003; Leser and Lamb 2005).
The matrix protein (M1), nuclear export protein, and the
nucleoprotein move to the nucleus and form the nucleo-
capsid. The nucleocapsid translocates the viral genome to the
cytosol and finally to the plasma membrane, where the new
virus particles are assembled and released. Viperin exerts its
effects at the later stages of this life cycle by preventing the
release of viral particles and appears to do this by disrupting
lipid rafts. Viperin achieves this effect by binding to and
inhibiting farnesyl diphosphate synthase (FPPS), an enzyme
involved in cholesterol and isoprenoid biosynthesis. It is
unclear exactly how this effect on FPPS leads to disruption of
lipid rafts, and future studies will no doubt uncover the
mechanisms involved. In addition to influenza virus retro-
viruses (eg, human immunodeficiency virus-1), para-
myxoviruses (eg, Sendai and measles) and filoviruses (eg,
Ebola) have all been linked to lipid rafts either for their entry
into, or exit from cells (Ono and Freed 2005). It is likely
therefore that Viperin may target lipid rafts to also interfere
with these viruses.
The ability of Viperin to disrupt lipid rafts does not ex-
plain its antiviral activity against other viruses, however.
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FIG. 1. Phylogenetic tree showing the evolutionary conservation of RSAD2 (Viperin) (a) and the domain organization of the
human Viperin gene (b). RSAD2, radical S-adenosyl methionine domain-containing 2.
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Viperin limits replication of HCV, a virus that does not bud
from lipid rafts (Helbig and others 2005; Hinson and Cress-
well 2009a, 2009b). HCV is a positive-sense, single-stranded
RNA virus that is packaged into an enveloped virus particle
(Dustin and Rice 2007; Randall and others 2007). Its genome
encodes one open reading frame translated into a single
polyprotein with*3,000 amino acids, which is both co- and
post-translationally cleaved at the membrane of the ER by
host and viral proteases into 3 structural (core, E1, and E2)
and 7 nonstructural proteins (p7, NS2, NS3, NS4A, NS4B,
NS5A, and NS5B). To initiate its life cycle, HCV particles are
internalized by clathrin-dependent endocytosis. Viral and
cellular membranes are then thought to fuse at the acidic
compartment and the genome is then released into the cy-
toplasm. The viral proteins are processed from a polyprotein
translated from the genomic RNA. For viral RNA replication,
a membrane-associated replication complex, composed of
viral nonstructural proteins, replicating RNA, and cellular
membranes, is formed. Enveloped HCV virions carrying a
newly synthesized viral genome appear to form by budding
into the ER lumen and then they leave the cells through the
secretory pathway. The HCV core protein initially localizes
to the cytosolic face of the ER. After maturation, the core
relocalizes to lipid droplets. Lipid droplets are cellular lipid
storage organelles not only involved in lipid storage and
trafficking but also now implicated in a variety of metabolic
diseases.
Chronic HCV infection affects host lipid metabolism, and
induces lipid droplet accumulation in the liver [reviewed in
(Fukasawa 2010)]. The core protein of HCV recruits the HCV
nonstructural proteins and the replication complex to lipid
droplets. Several of the NS proteins contain amphipathic a-
helices that are thought to facilitate interactions with the ER
(Elazar and others 2003, 2004; Suzuki and others 2005). The
N-terminal a-helices of Viperin also localize Viperin to the
lipid droplets (Hinson and Cresswell 2009a, 2009b). It is
likely that Viperin associates with lipid droplets as they form
from the outer leaflet of ER membranes. Exactly how Viperin
interferes with HCV replication within these organelles is
unclear. The number, size, or location of lipid droplets does
not appear to change when Viperin is present; however,
similar studies have not been done in HCV-infected cells. It is
possible that in the context of infection, Viperin alters lipid
droplet formation or the ability of the HCV proteins to lo-
calize to this organelle. This is an attractive possibility given
the ability of Viperin to alter ER membranes and lead to
curvature of ER membranes (Drin and others 2007; Drin and
Antonny 2010). Perhaps Viperin alters lipid droplet forma-
tion or morphology during infection. Another possibility is
that Viperin changes the lipid content of these organelles
through its actions on FPPS. Given that lipid droplets are
derived from the ER where cholesterol synthesis occurs, it is
possible that Viperin affects the type or quantity of lipids that
accumulate in the ER membrane leaflet and thus affect the
lipid content of lipid droplets.
Regardless of the exact mechanism of action of Viperin, its
high inducibility in various cell types indicates that this gene
plays a central role in antiviral defenses. The regulation of
Viperin gene expression is somewhat complicated. Its ex-
pression has been shown to be dependent on IFN production
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FIG. 2. Schematic representation of the antiviral action of Viperin against influenza and HCV. Viperin prevents HCV
assembly and/or budding by binding to lipid droplets that are essential for HCV replication. In the case of influenza virus,
Viperin binds to farnesyl diphosphate synthase, and thereby disrupts lipid rafts to prevent virus release. TheX indicates the
site of action of Viperin. HCV, hepatitis C virus; ER, endoplasmic reticulum; LD, lipid droplets; vRNA, viral RNA.
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and autocrine/paracrine IFN signaling in a number of set-
tings. A variety of pathways have now been described leading
to transcriptional regulation of IFN-b [reviewed in (Bowie and
Unterholzner 2008; Hornung and Latz 2010)]. Viperin has
been shown to be induced downstream of toll like receptor
(TLR)3, TLR4, retinoic acid induced gene (RIG)-I, and
melanoma differentiation associated (MDA5), as well as
downstream of cytosolic DNA sensing pathways, which use
some of these same components to turn on IFNB gene
expression. In the case of RIG-I signaling triggered by Sendai
virus, mitochondrial associated antiviral signaling (MAVS),
TANK (TRAF family member-associated NFKB activator)
binding kinase (TBK1), and a combination of interferon
regulatory factor (IRF)3 and 7 drive IFNB production, which
then signals via the IFNa/bR to induce Viperin. Viperin is not
induced in bone marrow macrophages derived from alpha/
beta IFN (IFN-a/b) receptor-deficient mice (Severa and others
2006). The key factor regulating Viperin promoter activity in
this system is the interferon-stimulated gene factor 3 (ISGF3)
complex and not IRF3 itself. Lipopolysaccharide and poly(I-C)
also induce Viperin expression through an ISGF3-mediated
pathway (Severa and others 2006).
It is also known that some ISGs, including Viperin, are
induced directly by IRF-3 itself (Grandvaux and others 2002).
vesicular stomatitis virus (VSV) directly induces Viperin
expression because treatment with anti-IFN antibody has no
effect on its induction. Similar studies were conducted with
the fish vig-1 gene, where neither anti-IFN antibodies nor
cycloheximide, which blocked de novo protein synthesis, in-
terfered with its induction (Boudinot and others 2000). Key
insights into this direct pathway of Viperin induction were
recently revealed. Direct induction of Viperin was shown to
be mediated by a pathway involving MAVS, the adapter
molecule downstream of RIG-I. MAVS is localized to both
mitochondria and peroxisomes and it is from this latter lo-
cation that direct induction of Viperin occurs (Dixit and
others 2010). Peroxisomal MAVS functions early to establish
an immediate although transient anti-viral state within the
cell, which can halt or delay viral replication until the more
robust and sustained antiviral response driven by the mito-
chondrial MAVS pathway come into play. VSV appears to
utilize this peroxisomal MAVS mechanism to turn on Vi-
perin gene expression.
It is not surprising that viral evasion mechanisms exist to
counteract Viperin itself. This has recently been revealed in
the case of Japanese encephalitis virus ( JEV) (Chan and
others 2008). Viperin is highly induced by JEV and the Vi-
perin protein is degraded in JEV-infected cells through a
proteasome-dependent mechanism. Overexpression of Vi-
perin had no effect on JEV replication, whereas the protea-
some inhibitor MG132 sustained the protein level and
antiviral effect of Viperin in JEV-infected cells. Consistent
with this model, knockdown of Viperin by RNA interference
had no effect on JEV replication. These findings suggest that
even though Viperin gene expression is highly induced by
JEV, it is negatively regulated at the protein level to coun-
teract its antiviral effect.
Future studies will likely unveil additional immune eva-
sion strategies employed by viruses to subvert the action of
Viperin. Despite the considerable progress that has been
made in our understanding of how Viperin controls virus
infection, a key mechanistic understanding of its mode of
action awaits further clarification. Viperin-deficient mice
have been generated; however, studies to examine their
susceptibility to viruses have not yet been revealed. In ad-
dition to its induction by viruses and viral nucleic acids, the
ability of other pathogens, and nonviral microbial products
such as LPS to induce this gene suggests a broader role
for Viperin in innate defenses. In this regard, Viperin
has recently been shown to be induced in neutrophils
and macrophages and is localized to the ER and lipid
droplet-like vesicles in neutrophils. In this context, it will
be of great interest to further elaborate the molecular
basis for Viperin action in these cells and delineate its role in
the regulation of the immune response to other classes of
pathogens such as bacteria that also induce Viperin to high
levels.
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